Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. The Group’s main products are contrast agents sold in over 100 countries, both directly and indirectly through branches, joint ventures and license and distribution agreements.
Come Responsabile di Zona (RDZ), avrai la responsabilità dello sviluppo e della gestione dell'area di competenza, assicurando al contempo:
Bracco Imaging – Divisione Italia, in accordo con le direttive del Responsabile del Servizio Scientifico, del Responsabile del Servizio di Farmacovigilanza, dei regolamenti e delle disposizioni aziendali nonché con le linee di sviluppo decise a livello di Gruppo;
Assicura per la propria zona di competenza:
Secondo la normativa italiana (Art. 122 del D.Lgs. 219/06 e decreti ministeriali successivi), per svolgere la professione di Informatore Scientifico del Farmaco (ISF) è richiesto uno dei seguenti titoli:
La posizione è inquadrata al Livello A ai sensi del Contratto Collettivo Nazionale di Lavoro per gli addetti all’industria chimica, chimico-farmaceutica (CCNL Chimico-Farmaceutico).
Lo stipendio base lordo annuo minimo garantito previsto dal CCNL per questo livello è pari a 46.518,36€.
Il pacchetto retributivo prevede inoltre un sistema incentivante variabile annuale, collegato al raggiungimento di obiettivi aziendali e individuali, nonché i benefit previsti dal contratto collettivo applicabile e dalle policy aziendali.
La retribuzione complessiva sarà definita sulla base di criteri oggettivi e neutrali rispetto al genere, tenendo conto dell’esperienza professionale maturata e delle competenze richieste per il ruolo.
Permanent
If you meet the requirements of this opportunity and would like to join an international group working to improve patients' lives, apply now!
At Bracco, we believe in the values of diversity and inclusion. We respect and celebrate the diversity of our people and their experiences, ensuring a fair opportunity for all.

Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,700 employees and annual total consolidated revenues of around 1,7 billion euros, 89% of which from international sales. In the R&D area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors. The Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Bracco offers an extensive and innovative portfolio of products and solutions for all diagnostic modalities completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by it’s American company ACIST. Since its foundation, Bracco has been a socially responsible company in each area of activity - in business as in every other context. Its subsidiary Bracco Imaging is one of the world’s leading companies in the diagnostic imaging field :X-Ray Imaging (including Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound, and Nuclear Medicine. The Company operates in over 110 markets: in North America through Bracco Diagnostics Inc. USA , and with an affiliate in Montreal (Canada); in Europe, with offices in all major countries; in Japan (BRACCO-EISAI). The Company also operates in South America, South Korea and China through its 70% controlled Joint Venture, Bracco Sine Pharmaceutical Corp. Ltd.